Teva Cleared for Iron Treatment

The product is the equivalent of Novartis' Desferal for Injection.
Author:
Publish date:

Teva Pharmaceutical

(TEVA) - Get Report

got Food and Drug Administration clearance to sell deferoxamine mesylate for injection.

The product is the generic equivalent of

Novartis'

Desferal for injection, a product indicated for acute treatment of iron intoxication and chronic iron overload due to transfusion-dependent anemias. Shipment of the product will begin immediately, it said.

Total annual sales of deferoxamine mesylate for injection are about $43 million.

This story was created through a joint venture between TheStreet.com and IRIS.